Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib versus durvalumab in ALK-positive unresectable stage III non-small cell lung cancer after chemoradiotherapy
MOH_2023-11-13_013043Phase 3Recruiting
- Sponsor
- Roche
- Start
- Nov 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing A1 alectinib arm with A1 durvalumab comparator arm (2 arms). Started Nov 2023; status: recruiting.
02
Drugs
alectinibdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2023-11-13_013043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-11-13_013043.